McFarlane Neil F.
Insider CIK 1681098 · COLL Director · ADMS Chief Executive Officer, Director · ZVRA President and CEO, Director · RTRX Chief Operating Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2026-10-12 | 2026-10-13 | 20,000 | $11.25 | $224.9K | 417,225 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise deriv | 2026-10-10 | 2026-10-13 | 50,000 | — | $0 | 50,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise | 2026-10-10 | 2026-10-13 | 50,000 | — | — | 437,225 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2026-02-09 | 2026-02-10 | 14,625 | $8.56 | $125.2K | 387,225 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise deriv | 2026-02-07 | 2026-02-10 | 37,500 | — | $0 | 75,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise | 2026-02-07 | 2026-02-10 | 37,500 | — | $0 | 401,850 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2026-02-02 | 2026-02-02 | 91,000 | $9.38 | $853.6K | 364,350 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise deriv | 2026-01-31 | 2026-02-02 | 233,334 | — | $0 | 233,333 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise | 2026-01-31 | 2026-02-02 | 233,334 | — | $0 | 455,350 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2026-01-29 | 2026-02-02 | 250,000 | — | $0 | 250,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2026-01-29 | 2026-02-02 | 125,000 | — | $0 | 125,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise deriv | 2025-10-10 | 2025-10-10 | 50,000 | — | $0 | 100,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2025-10-10 | 2025-10-10 | 19,500 | $10.82 | $211.0K | 222,016 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise | 2025-10-10 | 2025-10-10 | 50,000 | — | $0 | 241,516 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2025-02-14 | 2025-02-14 | 30,544 | $8.05 | $245.9K | 191,516 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | S Sale | 2025-02-13 | 2025-02-14 | 61,273 | $7.86 | $481.6K | 222,060 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2025-02-07 | 2025-02-10 | 225,000 | — | $0 | 225,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2025-02-07 | 2025-02-10 | 112,500 | — | $0 | 112,500 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise deriv | 2025-01-31 | 2025-02-03 | 233,333 | — | $0 | 466,667 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | M Exercise | 2025-01-31 | 2025-02-03 | 233,333 | — | $0 | 283,333 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2024-05-16 | 2024-05-16 | 7,693 | — | $0 | 49,365 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2024-01-31 | 2024-02-02 | 700,000 | — | $0 | 700,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2023-10-10 | 2023-10-11 | 200,000 | — | $0 | 200,000 | SEC↗ |
| ZVRA ZEVRA THERAPEUTICS, INC. | A Award deriv | 2023-10-10 | 2023-10-11 | 600,000 | — | $0 | 600,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2023-05-18 | 2023-05-19 | 9,792 | — | $0 | 41,672 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2022-05-19 | 2022-05-23 | 14,035 | — | $0 | 31,880 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2022-04-06 | 2022-04-08 | 17,845 | — | $0 | 17,845 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | D To issuer deriv | 2021-11-24 | 2021-11-24 | 250,000 | — | $0 | 0 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | D To issuer deriv | 2021-11-24 | 2021-11-24 | 200,000 | — | $0 | 0 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | U Tender | 2021-11-24 | 2021-11-24 | 600,000 | — | $0 | 0 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award | 2021-11-24 | 2021-11-24 | 75,000 | — | $0 | 600,000 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award | 2021-03-02 | 2021-03-03 | 300,000 | — | $0 | 525,000 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award deriv | 2020-03-18 | 2020-03-20 | 200,000 | — | $0 | 200,000 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award | 2020-03-18 | 2020-03-20 | 100,000 | — | $0 | 225,000 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award deriv | 2019-09-16 | 2019-09-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| ADMS Adamas Pharmaceuticals Inc | A Award | 2019-09-16 | 2019-09-17 | 125,000 | — | $0 | 125,000 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2019-05-16 | 2019-05-16 | 984 | $18.71 | $18.4K | 26,988 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2019-05-15 | 2019-05-16 | 984 | $17.78 | $17.5K | 27,972 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2018-12-20 | 2018-12-21 | 4,721 | $22.00 | $103.9K | 35,360 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2018-12-20 | 2018-12-21 | 6,404 | $22.56 | $144.5K | 28,956 | SEC↗ |
| RTRX Retrophin, Inc. | A Award | 2018-12-18 | 2018-12-20 | 11,125 | — | $0 | 40,081 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2018-11-14 | 2018-11-16 | 9,000 | $23.63 | $212.7K | 29,476 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2018-11-14 | 2018-11-16 | 1,000 | $24.64 | $24.6K | 28,476 | SEC↗ |
| RTRX Retrophin, Inc. | A Award | 2018-11-09 | 2018-11-14 | 10,000 | — | $0 | 38,476 | SEC↗ |
| RTRX Retrophin, Inc. | A Award deriv | 2018-05-10 | 2018-05-14 | 63,000 | — | $0 | 63,000 | SEC↗ |
| RTRX Retrophin, Inc. | A Award deriv | 2018-05-10 | 2018-05-14 | 10,500 | — | $0 | 10,500 | SEC↗ |
| RTRX Retrophin, Inc. | A Award | 2018-05-10 | 2018-05-14 | 10,500 | — | $0 | 27,948 | SEC↗ |
| RTRX Retrophin, Inc. | A Award | 2018-02-08 | 2018-02-12 | 2,546 | — | $0 | 17,448 | SEC↗ |
| RTRX Retrophin, Inc. | S Sale | 2017-08-16 | 2017-08-17 | 1,378 | $22.50 | $31.0K | 13,622 | SEC↗ |
| RTRX Retrophin, Inc. | A Award deriv | 2017-05-17 | 2017-05-18 | 90,000 | — | $0 | 90,000 | SEC↗ |
| RTRX Retrophin, Inc. | A Award deriv | 2016-08-15 | 2016-08-15 | 120,000 | — | $0 | 120,000 | SEC↗ |
| RTRX Retrophin, Inc. | A Award | 2016-08-15 | 2016-08-15 | 15,000 | — | $0 | 15,000 | SEC↗ |